


Interview Sumn	Application No. Applicant(s) 08/468,381 Lin	
	Examiner James Martinell at	Group Art Unit 1804
All participants (applicant, applicant's representative, f	PTO personnel):	
(1) James Martinell	(3) Mr. Watt	
(2) Mr. Borun		
Date of Interview Dec 11, 1996		ų
Type: 🔲 Telephonic - 🖾 Personal (copy is given to		t's representative).
Exhibit shown or demonstration conducted: X Yes Proposed claims A-E.	□ No. If yes, brief descrip	tion:
Agreement 🔲 was reached. 🛭 was not reached.	1	
Claim(s) discussed: 61, 62, 68, and 69.		
Identification of prior art discussed: None.		
Figure 6. Additionally, applicant intends to file a Term Applicant will point to basis in application for the non-		
(A fuller description, if necessary, and a copy of the a the claims allowable must be attached. Also, where r is available, a summary thereof must be attached.)		
1. It is not necessary for applicant to provide a s	eparate record of the substance	e of the interview.
Unless the paragraph above has been checked to indic LAST OFFICE ACTION IS NOT WAIVED AND MUST II Section 713.04). If a response to the last Office action FROM THIS INTERVIEW DATE TO FILE A STATEMEN	NCLUDE THE SUBSTANCE OF on has already been filed, APPL	THE INTERVIEW. (See MPEP
 Since the Examiner's interview summary above each of the objections, rejections and requirent claims are now allowable, this completed form Office action. Applicant is not relieved from p is also checked. 	nents that may be present in the rest of the considered to fulfill the rest	ne last Office action, and since the points requirements of the last the interview unless box 1 above
	Ŝ	MÉS MARTINELL, PH.D. NIOR LEVEL EXAMINER
Examiner Note: You must sign and stemp this form unless it is	an attachment to a signed Office a	ction.GROUP 1800
Psum and Trademan Office O-413 (Rev. 10-95)	terview Summary	Paper No. 7

A 41588

158

AM670113668



CLAIMS FOR DISCUSSION WITH RESPECT TO SERIAL NOS. 08/468,369, 08/468,381 AND 08/468,556

- An isolated erythropoietin glycoprotein having the in vivo biological activity of causing bone marrow cells to increase production of reticulocytes and red blood cells, wherein said erythropoietin glycoprotein comprises the mature erythropoietin amino acid sequence of Figure 6 and has glycosylation which differs from that of human urinary erythropoietin.
- В. An isolated erythropoietin glycoprotein having the in vivo biological activity of causing bone marrow cells to increase production of reticulocytes and red blood cells, wherein said erythropoietin glycoprotein comprises the mature erythropoietin amino acid sequence of Figure 6 and is not isolated from human urine.
 - A process for producing erythropoietin comprising the steps of:
- a) growing, under suitable nutrient conditions, host cells transformed or transfected with DNA encoding the mature erythropoietin amino acid sequence of Figure 6; and
 - b) isolating erythropoietin produced by said host cells.

A 41589

159

AM670113669 AM-ITC 00898336



A process for the production of a glycosylated erythropoietin polypeptide having the in vivo biological property of causing bone marrow cells to increase production of reticulocytes and red blood cells comprising the steps of:

a) growing, under suitable nutrient conditions, vertebrate cells comprising promoter DNA, other than human erythropoietin promoter DNA, operatively linked to DNA encoding the mature erythropoietin amino acid sequence of Figure 6; and b) isolating said glycosylated erythropoietin polypeptide expressed by said cells.

- A process for the production of a glycosylated erythropoietin polypeptide having the in vivo biological property of causing bone marrow cells to increase production of reticulocytes and red blood cells comprising the steps of:
- a) growing, under suitable nutrient conditions, vertebrate cells comprising amplified DNA encoding the mature erythropoietin amino acid sequence of Figure 6; and
- b) isolating said glycosylated erythropoietin polypeptide expressed by said cells.

[The erythropoietin product of processes C, D and E]

A 41590

160



AM670113670